Gennady Vasilievich Roshchupkin

Gennady Vasilievich Roshchupkin

Auto-generated profile, based on publicly available information

Gennady Vasilievich Roshchupkin

Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BKBrian W. Kunkle
Brian W. Kunkle
T(The European Alzheimer’s Disease Initiative (Eadi)
The European Alzheimer’s Disease Initiative (Eadi)
BGBenjamin Grenier-Boley
Benjamin Grenier-Boley
RSRebecca Sims
Rebecca Sims
JBJoshua C. Bis
Joshua C. Bis
MPMargaret A. Pericak-Vance
Margaret A. Pericak-Vance

30 September 2022 in Nature
Verified
Journal Article
Open access
PDF file
AMAniket Mishra
Aniket Mishra
RMRainer Malik
Rainer Malik
THTsuyoshi Hachiya
Tsuyoshi Hachiya
TJTuuli Jürgenson
Tuuli Jürgenson
SNShinichi Namba
Shinichi Namba
SDStephanie Debette
Stephanie Debette
Previous genome-wide association studies (GWASs) of stroke — the second leading cause of death worldwide — were conducted predominantly in populations of European ancestry1,2. Here, in cross-ancestry GWAS meta-analyses of 110,182 patients who have had a stroke (five ancestries, 33% non-European) and 1,503,898 control individuals, we identify association signals for stroke and its subtypes at 89 (61 new) independent loci: 60 in primary inverse-variance-weighted analyses and 29 in secondary meta-regression and multitrait analyses. On the basis of internal cross-ancestry validation and an independent follow-up in 89,084 additional cases of stroke (30% non-European) and 1,013,843 control individuals, 87% of the primary stroke risk loci and 60% of the secondary stroke risk loci were replicated (P < 0.05). Effect sizes were highly correlated across ancestries. Cross-ancestry fine-mapping, in silico mutagenesis analysis3, and transcriptome-wide and proteome-wide association analyses revealed putative causal genes (such as SH3PXD2A and FURIN) and variants (such as at GRK5 and NOS3). Using a three-pronged approach4, we provide genetic evidence for putative drug effects, highlighting F11, KLKB1, PROC, GP1BA, LAMC2 and VCAM1 as possible targets, with drugs already under investigation for stroke for F11 and PROC. A polygenic score integrating cross-ancestry and ancestry-specific stroke GWASs with vascular-risk factor GWASs (integrative polygenic scores) strongly predicted ischaemic stroke in populations of European, East Asian and African ancestry5. Stroke genetic risk scores were predictive of ischaemic stroke independent of clinical risk factors in 52,600 clinical-trial participants with cardiometabolic disease. Our results provide insights to inform biology, reveal potential drug targets and derive genetic risk prediction tools across ancestries.

21 October 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CSClaudia L Satizabal
Claudia L Satizabal
HAHieab H H Adams
Hieab H H Adams
DHDerrek P Hibar
Derrek P Hibar
CWCharles C White
Charles C White
MKMaria J Knol
Maria J Knol
MIM Arfan Ikram
M Arfan Ikram

15 October 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JWJohnny Wang
Johnny Wang
MKMaria J. Knol
Maria J. Knol
ATAleksei Tiulpin
Aleksei Tiulpin
FDFlorian Dubost
Florian Dubost
MBMarleen de Bruijne
Marleen de Bruijne
GRGennady V. Roshchupkin
Gennady V. Roshchupkin
The gap between predicted brain age using magnetic resonance imaging (MRI) and chronological age may serve as a biomarker for early-stage neurodegeneration. However, owing to the lack of large longitudinal studies, it has been challenging to validate this link. We aimed to investigate the utility of such a gap as a risk biomarker for incident dementia using a deep learning approach for predicting brain age based on MRI-derived gray matter (GM). We built a convolutional neural network (CNN) model to predict brain age trained on 3,688 dementia-free participants of the Rotterdam Study (mean age 66 ± 11 y, 55% women). Logistic regressions and Cox proportional hazards were used to assess the association of the age gap with incident dementia, adjusted for age, sex, intracranial volume, GM volume, hippocampal volume, white matter hyperintensities, years of education, and APOE ε4 allele carriership. Additionally, we computed the attention maps, which shows which regions are important for age prediction. Logistic regression and Cox proportional hazard models showed that the age gap was significantly related to incident dementia (odds ratio [OR] = 1.11 and 95% confidence intervals [CI] = 1.05–1.16; hazard ratio [HR] = 1.11, and 95% CI = 1.06–1.15, respectively). Attention maps indicated that GM density around the amygdala and hippocampi primarily drove the age estimation. We showed that the gap between predicted and chronological brain age is a biomarker, complimentary to those that are known, associated with risk of dementia, and could possibly be used for early-stage dementia risk screening. Significance The difference between brain age estimated from MRI and chronological age is thought to serve as an important biomarker reflecting pathological processes in the brain. Several recent studies showed the relation between accelerated brain aging and various disorders. However, until now, the utility of such an age difference for preclinical screening using longitudinal studies was absent. To fill this gap, we first built a deep learning model using brain MRI from a population-based study including 5,496 participants. And then, using follow-up information, we observed that this age difference was significantly associated with the risk of dementia. Therefore, our study shows that the difference between MRI-brain predicted and chronological age is potentially a biomarker for early dementia risk screening.

5 April 2022 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
RBRachel M. Brouwer
Rachel M. Brouwer
MKMarieke Klein
Marieke Klein
KGKatrina Grasby
Katrina Grasby
HSHugo G. Schnack
Hugo G. Schnack
NJNeda Jahanshad
Neda Jahanshad
HPHilleke E. Hulshoff Pol
Hilleke E. Hulshoff Pol

17 April 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MDMarie-Gabrielle Duperron
Marie-Gabrielle Duperron
MKMaria J. Knol
Maria J. Knol
QGQuentin Le Grand
Quentin Le Grand
TETavia E. Evans
Tavia E. Evans
AMAniket Mishra
Aniket Mishra
SDStéphanie Debette
Stéphanie Debette
Perivascular space (PVS) burden is an emerging, poorly understood, magnetic resonance imaging marker of cerebral small vessel disease, a leading cause of stroke and dementia. Genome-wide association studies in up to 40,095 participants (18 population-based cohorts, 66.3 ± 8.6 yr, 96.9% European ancestry) revealed 24 genome-wide significant PVS risk loci, mainly in the white matter. These were associated with white matter PVS already in young adults (N = 1,748; 22.1 ± 2.3 yr) and were enriched in early-onset leukodystrophy genes and genes expressed in fetal brain endothelial cells, suggesting early-life mechanisms. In total, 53% of white matter PVS risk loci showed nominally significant associations (27% after multiple-testing correction) in a Japanese population-based cohort (N = 2,862; 68.3 ± 5.3 yr). Mendelian randomization supported causal associations of high blood pressure with basal ganglia and hippocampal PVS, and of basal ganglia PVS and hippocampal PVS with stroke, accounting for blood pressure. Our findings provide insight into the biology of PVS and cerebral small vessel disease, pointing to pathways involving extracellular matrix, membrane transport and developmental processes, and the potential for genetically informed prioritization of drug targets.